Hot Pursuit     15-Jun-24
Biocon’s Andhra Pradesh facility gets 3 USFDA observations
Biocon said that US Food and Drug Administration (USFDA) issued three observations after the good manufacturing practices (GMP) inspection conducted at its API manufacturing facility situated at Visakhapatnam, Andhra Pradesh.
The good manufacturing practices was conducted on 14 June 2024 and closed the inspection with three observations. The company said that it will respond to the USFDA within the stipulated timeframe.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported 56.74% decline in consolidated net profit to Rs 135.5 crore despite of 3.79% rise in revenue from operations to Rs 3,917.1 crore in Q4 FY24 over Q4 FY23.

The scrip fell 1.06% to end at Rs 334.65 on Friday, 15 June 2024.

Previous News
  Benchmarks trade falt; oil & gas shares rally for 9th day in row
 ( Market Commentary - Mid-Session 24-May-24   12:33 )
  Biocon reports consolidated net profit of Rs 660.00 crore in the December 2023 quarter
 ( Results - Announcements 09-Feb-24   07:41 )
  Barometers pares all gains ; realty shares decline
 ( Market Commentary - Mid-Session 24-May-24   10:36 )
  Biocon surges after signing exclusive licensing deal for Liraglutide with Handok
 ( Hot Pursuit - 24-May-24   09:45 )
  Biocon announces resignation of senior management
 ( Corporate News - 08-Feb-24   19:49 )
  Biocon gains after subsidiary secures 'Yesafili' entry into Canadian market
 ( Hot Pursuit - 04-Mar-24   11:42 )
  Biocon subsidiary launches biosimilar for Humira in US
 ( Hot Pursuit - 04-Jul-23   08:56 )
  Biocon Biologics divests its non-crore branded formulations biz in India
 ( Corporate News - 10-Nov-23   12:06 )
 ( Results - Analysis 16-Nov-22   18:05 )
  Volumes jump at Biocon Ltd counter
 ( Hot Pursuit - 28-Feb-23   11:00 )
  Biocon appoints director
 ( Corporate News - 12-Dec-22   19:04 )
Other Stories
  Lupin receives EIR from USFDA for Dabhasa facility
  13-Jul-24   16:48
  RVNL secures LoA worth Rs 132 cr from Central Railway
  13-Jul-24   16:38
  EMS bags order worth Rs 141-cr from Uttarakhand Power Corp.
  13-Jul-24   16:14
  Avenue Supermarts Q1 PAT climbs 17% YoY to Rs 774 cr in FY25
  13-Jul-24   16:00
  Sunteck Realty pre-sales climbs 30% YoY to Rs 502 cr in FY25
  13-Jul-24   15:32
  Fitch Ratings revises outlook on ratings of Tata Steel to 'negative'
  13-Jul-24   14:46
  5Paisa Capital Q1 PAT jumps 38% YoY in FY25
  13-Jul-24   14:39
  HCL Tech records PAT of Rs 4,257 crore in Q1; EBIT margin at 17.1%
  13-Jul-24   11:59
  IREDA Q1 PAT rises 30% YoY to Rs 384 cr in FY25
  13-Jul-24   09:00
  GTPL Hathway slides after Q1 PAT drops 60% YoY to Rs 14 cr in FY25
  12-Jul-24   15:40
Back Top